Avoro Capital Advisors’s Blueprint Medicines BPMC Stock Holding History

Avoro Capital Advisors’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-375,000	Closed	-$48.1M	–	33
2025 Q2	$48.1M	Sell	375,000 -3,475,000	-90%	-$361M	0.84%	23
2025 Q1	$341M	Buy	3,850,000 +2,665,000	+225%	+$260M	5.32%	6
2024 Q4	$103M	Buy	+1,185,000	New	+$109M	1.46%	17
2017 Q2	–	Sell	-165,000	Closed	-$6.6M	–	48
2017 Q1	$6.6M	Buy	+165,000	New	+$5.91M	0.84%	28

Other funds holding BPMC

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Avoro Capital Advisors's BPMC Position: Q3 2025 in Review

Avoro Capital Advisors sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 375,000 shares — an estimated $48.1M sold.

Avoro Capital Advisors first reported a position in BPMC in Q1 2017 and held it in 4 quarters. The position peaked at $341M in Q1 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

Avoro Capital Advisors reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
Avoro Capital Advisors sold 375,000 Blueprint Medicines shares in Q3 2025, an estimated $48.1M.
Avoro Capital Advisors first reported a position in Blueprint Medicines in Q1 2017 and held it in 4 quarters.
Avoro Capital Advisors's Blueprint Medicines position peaked at $341M in Q1 2025.
5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Avoro Capital Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.